Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-03-20
2007-03-20
Chism, B. Dell (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S114000, C514S221000, C514S234200, C514S248000, C514S249000, C514S250000, C514S378000
Reexamination Certificate
active
10398876
ABSTRACT:
This invention relates to methods for the treatment or prevention of central nervous system (CNS) cell damage and functional damage in mammals due to demyelinating disease including multiple sclerosis. More specifically, the invention comprises a method of treating a demyelinating disease of the CNS in a mammal, the method comprising co-administering to the mammal, either sequentially or simultaneously, GPE or analogues or peptidomimetics or a prodrug thereof, or a pharmaceutically acceptable salt thereof, and an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate)/kainate antagonist, or a pharmaceutically acceptable salt thereof, and an anti-inflammatory agent.
REFERENCES:
patent: WO 95/17204 (1995-06-01), None
patent: WO 00 01376 (2000-01-01), None
Smith et al., Jan. 2000, Nature Medicine, vol. 6, No. 1, pp. 62-66.
Guan et al., Mar. 2000, Brain Research, vol. 859, No. 2, pp. 286-292.
Smith, et al.: “Autoimmune encephalomyelitis ameliorated by AMPA antagonists”, Nature Medicine. U.S. Jan. 2000, vol. 6, No. 1. pp 62-66.
Guan, J., et al: “N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats.”, Brain Research, Netherlands Mar. 24, 2000, vol. 859, No. 2. pp. 286-292.
Kanwar, J.R., et al: “Beta7 integrins contribute to demyelinating disease of the central nervous system.”, Journal of Neuroimmunology. Netherlands Mar. 1, 2000, vol. 103, No. 2 pp. 146-152.
Kanwar Jagat Rakesh
Krissansen Geoffrey Wayne
Chism B. Dell
Fliesler & Meyer LLP
Neuren Pharmaceuticals Ltd.
LandOfFree
Treatment of demyelinating diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of demyelinating diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of demyelinating diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3776995